Introduction
============

As a cancerous tumor that originates from bone, osteosarcoma (OS) is the most frequent histological type of primary bone cancer ([@b1-ijmm-41-03-1233]). It is usually derived from tubular long bones, with 10% occurring in the humerus, 19% in the tibia and 42% in the femur ([@b2-ijmm-41-03-1233]). OS is the eighth most common type of cancer in pediatric patients, accounting for \~20% of all primary bone cancers and 2.4% of all malignancies in children ([@b3-ijmm-41-03-1233]). OS usually occurs in young adults and teenagers, and may be treated by surgical resection of the cancer ([@b4-ijmm-41-03-1233]). Although \~90% of OS patients undergo limb-salvage surgery, the subsequent complications (such as infection, local tumor recurrence, prosthetic non-union and loosening) may result in further surgery or amputation ([@b5-ijmm-41-03-1233]). Thus, revealing the underlying mechanisms of OS is considered to be important for improving therapeutic strategies.

Through activating the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, metastasis-associated lung adenocarcinoma transcript 1 contributes to proliferation and metastasis of OS and serves as a therapeutic target for OS patients ([@b6-ijmm-41-03-1233],[@b7-ijmm-41-03-1233]). Transforming growth factor-α (TGF-α)/epidermal growth factor receptor (EGFR) interaction induces the activation of PI3K/Akt and nuclear factor-κB (NF-κB) signaling pathways, leading to intracellular cell adhesion molecule 1 (*ICAM1*) expression and promoting the metastasis of human OS cells ([@b8-ijmm-41-03-1233]). The low expression level of monocarboxylate transporter isoform 1 (*MCT1*) performs an antitumor role via the NF-κB signaling pathway, and the high expression level of *MCT1* predicts poor overall survival in OS patients ([@b9-ijmm-41-03-1233]). As a negative regulator of Wnt signaling, naked cuticle homolog 2 functions in inhibiting tumor growth and invasion of human OS ([@b10-ijmm-41-03-1233],[@b11-ijmm-41-03-1233]). Via activation of the cyclooxygenase-2 (*COX-2*) gene, p50-associated COX-2 extragenic RNA promotes the proliferation and invasion of OS cells ([@b12-ijmm-41-03-1233]). Although these studies have investigated the underlying mechanisms of OS metastasis, the key genes and signaling pathways involved in the metastasis of OS have not been fully reported.

In 2013, Kelly *et al* ([@b13-ijmm-41-03-1233]) performed formalin-fixed, paraffin-embedded assays to identify the miRNA biomarkers associated with OS prognosis, finding that the 14q32 locus was potential involved in the progression and outcome of OS. Using the data deposited by Kelly *et al* ([@b13-ijmm-41-03-1233]), the differentially expressed genes (DEGs) were identified between the OS biopsy specimens following metastasis and the OS biopsy specimens prior to metastasis. Subsequently, comprehensive bioinformatics analyses \[including clustering analysis, enrichment analysis, protein-protein network (PPI) analysis, calculation of function deviation score and logistic regression analysis\] were performed to identify the metastasis-associated terms. Finally, the metastasis-associated terms were further confirmed by other independent datasets.

Materials and methods
=====================

Microarray data
---------------

Gene expression profiling and clinical outcomes under GSE39055 were downloaded from the Gene Expression Omnibus database (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) database, which was based on the GEO platform, GPL14951, Illumina HumanHT-12 WG-DASL v4.0 R2 expression BeadChip. GSE39055 included 19 OS biopsy specimens before metastasis and 18 OS biopsy specimens after metastasis. The samples were acquired from the pathology archives of Boston Children's Hospital (Boston, USA) and Beth Israel Deaconess Medical Center (Boston, USA). Kelly *et al* ([@b13-ijmm-41-03-1233]) deposited GSE39055, and the study obtained the approval of the Institutional Review Boards at Boston Children's Hospital and Beth Israel Deaconess Medical Center with a waiver of consent.

DEG screening and clustering analysis
-------------------------------------

Based on the platform annotation information, all probe IDs were transformed into gene symbols. When one gene symbol corresponded to multiple probes, the gene expression value was obtained by calculating the average value of the probes. Subsequently, Z-score normalization was performed for all gene expression values. Using the Linear Models for Microarray Analysis package (<http://www.bioconductor.org/packages/release/bioc/html/limma.html>) ([@b14-ijmm-41-03-1233]) in R, the DEGs between the OS biopsy specimens after metastasis (case group) and the OS biopsy specimens before metastasis (control group) were analyzed. P\<0.05 and \|logFC (fold change)\| \>0.6 were set as the thresholds.

To confirm whether the DEGs were able to effectively distinguish between the two groups of samples, hierarchical clustering analysis was conducted using Orange software (version 3.4, <http://orange.biolab.si/citation/>) ([@b15-ijmm-41-03-1233]) and the result was visualized using a distance map ([@b16-ijmm-41-03-1233]). Pearson correlation coefficient ([@b17-ijmm-41-03-1233]) and average linkage ([@b18-ijmm-41-03-1233]) were performed separately for similarity algorithms and similarity matrices. Additionally, unsupervised clustering analysis was conducted for the samples using the self-organization map (SOM) method ([@b19-ijmm-41-03-1233]).

Functional and pathway enrichment analysis
------------------------------------------

The Gene Ontology (GO; <http://www.geneontology.org>) database provides information regarding cellular components (CCs), molecular function (MF), and biological processes (BPs) for gene produces ([@b20-ijmm-41-03-1233]). The Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.ad.jp/kegg>) is a database applied for conducting pathway analysis for genes or other molecules ([@b21-ijmm-41-03-1233]). Based on the Database for Annotation, Visualization and Integrated Discovery (DAVID; <https://david.ncifcrf.gov/>) tool ([@b22-ijmm-41-03-1233]), GO functional and KEGG pathway enrichment analyses were performed for the DEGs, with the threshold set at P\<0.05.

PPI network analysis
--------------------

Biological General Repository for Interaction Datasets (BioGrid; <http://www.thebiogrid.org>) is an interaction database that includes genetic and protein interactions for humans and all major model organism species ([@b23-ijmm-41-03-1233]). Human Protein Reference Database (HPRD; <http://www.hprd.org/>) is a comprehensive protein information resource that provides various features of human proteins ([@b24-ijmm-41-03-1233]). The PPI network data in BioGrid ([@b23-ijmm-41-03-1233]) and HPRD ([@b24-ijmm-41-03-1233]) databases were downloaded and merged. Then, the DEGs were mapped into the human PPI network to identify the PPIs among the DEGs. Subsequently, the PPI network for the DEGs was visualized using Cytoscape software (version 3.5.0, <http://www.cytoscape.org>) ([@b25-ijmm-41-03-1233]). In addition, the network analysis plug-in in Cytoscape software ([@b25-ijmm-41-03-1233]) was used to analyze network topological features to screen the hub nodes ([@b26-ijmm-41-03-1233]) in the PPI network.

Calculation of function deviation score
---------------------------------------

To obtain the results with stability and accuracy, function deviation scores were calculated for the significantly enriched terms. The formula was follows:

Where m and n separately represent the numbers of upregulated and downregulated genes enriched in term $P.\overline{d}$ represents the mean value of the upregulated gene, i or downregulated gene, j in the control group. ω represents the node degree of a gene in the PPI network. The Euclidean distance is used to calculate the degree of deviation of the term P influenced by the upregulated and downregulated genes. Function score \>0 indicates that the term P is upregulated in the case group compared with the control group. Function score \<0 indicates that the term P is downregulated in the case group compared with the control group. Combined with the function deviation scores, hierarchical clustering analysis was performed using Cluster 3.0 software ([@b27-ijmm-41-03-1233]) to verify whether these significantly enriched terms clearly distinguished the case group from the control group.

Identification of significantly different terms
-----------------------------------------------

To identify the terms with significant differences in OS biopsy specimens before/after metastasis, logistic regression analysis was performed to calculate the significance of each term. The terms with P\<0.05 were considered to be significantly different (also defined as metastasis-associated terms).

Validation of the metastasis-associated terms using other independent datasets
------------------------------------------------------------------------------

Two microarray datasets, GSE21257 (including 19 OS specimens without metastasis and 34 OS specimens with metastasis) and GSE32981 (including five OS specimens without metastasis and 18 OS specimens with metastasis) were downloaded from the European Molecular Biology Laboratory (<http://www.ebi.ac.uk/embl/index.html>) Nucleotide Sequence Database. Subsequently, the two datasets were merged and normalized. The OS specimens with/without metastasis were predicted, and the prediction accuracy was exhibited via receiver operating characteristic (ROC) curves. In addition, Kaplan-Meier (KM) survival analysis ([@b28-ijmm-41-03-1233]) was used to analyze the correlations between the survival times in GSE21257 and GSE16091 (downloaded from the GEO database) and the metastasis-associated terms.

The main risk factor for disease recurrence and metastasis is the sensitivity of patients to drug treatment, and metastasis/recurrence typically occurs when there is apparent drug resistance ([@b29-ijmm-41-03-1233]). Microarray data of GSE81892 (including 21 OS specimens with obvious resistance and 13 OS specimens with drug sensitivity) and GSE14827 (including 16 OS specimens with obvious resistance and 11 OS specimens with drug sensitivity) were downloaded from the GEO database. To confirm whether the metastasis-associated terms affect drug sensitivity and influence the risk of metastasis/recurrence, the terms were used to distinguish the OS specimens with obvious resistance and the OS specimens with drug sensitivity.

Results
=======

DEG analysis
------------

A total of 840 DEGs were identified in the case group compared with the control group, including 420 upregulated genes and 420 downregulated genes. After removing one abnormal sample, the remaining 36 samples were used for the subsequent analysis. Hierarchical clustering analysis demonstrated that 19 samples were included in the case group (accuracy, 95%) and 17 samples were included in the control group (accuracy, 100%) ([Fig. 1A](#f1-ijmm-41-03-1233){ref-type="fig"}). To further evaluate the correlation and distance between the two groups of samples, the distances between the remaining 36 samples were visualized using a distance map ([Fig. 1B](#f1-ijmm-41-03-1233){ref-type="fig"}). The distances between the intra-group samples tended to be closer, while the distances between the inter-group samples were relatively far apart. Meanwhile, unsupervised clustering analysis based on the SOM method demonstrated that the classification effect for the samples in the majority of neurons was good ([Fig. 2](#f2-ijmm-41-03-1233){ref-type="fig"}).

Functional and pathway enrichment analysis
------------------------------------------

The upregulated and downregulated genes separately underwent enrichment analysis. The GO terms that were enriched for the upregulated genes predominantly included regulation of cell migration (P=2.83E-12), blood vessel development (P=2.74E-10) and vasculature development (P=4.67E-10) ([Table I](#tI-ijmm-41-03-1233){ref-type="table"}). The upregulated genes were enriched in the KEGG pathways of viral myocarditis (P=7.85E-08), focal adhesion (P=3.70E-06) and endocytosis (P=1.44E-03) ([Table II](#tII-ijmm-41-03-1233){ref-type="table"}). In addition, the downregulated genes were predominantly enriched in the GO terms of RNA metabolic processes (P=1.11E-06), RNA processing (P=2.11E-06) and regulation of gene expression (P=5.20E-04) ([Table III](#tIII-ijmm-41-03-1233){ref-type="table"}). Furthermore, the KEGG pathways enriched for the downregulated genes were cell adhesion molecules (P=2.32E-09), extracellular matrix-receptor interaction (P=1.49E-08), and pathways in cancer (P=3.04E-02) ([Table IV](#tIV-ijmm-41-03-1233){ref-type="table"}).

PPI network analysis and function deviation score
-------------------------------------------------

The PPI network for the DEGs contained 409 nodes (including 195 upregulated and 214 downregulated genes) ([Fig. 3](#f3-ijmm-41-03-1233){ref-type="fig"}). Notably, there were various interactions \[including ICAM1-TGF-β1, TGFB1-platelet-derived growth factor β (PDGFB), and PDGFB-platelet derived growth factor receptor β (PDGFRB)\] in the PPI network. After calculating the function deviation scores of the significantly enriched terms, hierarchical clustering analysis was performed to verify whether these terms clearly distinguished the case group from the control group. The heat map demonstrated that almost all samples were clearly distinguished, indicating that the significantly enriched terms significantly changed at the functional level during OS metastasis ([Fig. 4](#f4-ijmm-41-03-1233){ref-type="fig"}).

Identification of significantly different terms
-----------------------------------------------

To identify the significantly different terms in the two groups of samples, logistic regression analysis was performed. The top 25 terms with P\<0.01 were listed in [Table V](#tV-ijmm-41-03-1233){ref-type="table"}, including regulation of cell migration (P=2.15E-05), nucleotide excision repair (P=1.31E-05), Wnt signaling pathway (P=2.32E-03), and cell migration (P=5.56E-03). Specifically, *ICAM1*, *PDGFB*, *PDGFRB* and *TGFB1* were enriched in cell migration and regulation of cell migration.

Validation of the metastasis-associated terms using other independent datasets
------------------------------------------------------------------------------

After the microarray datasets, GSE21257 and GSE32981 were merged and normalized, the OS specimens with/without metastasis were predicted. The ROC curves demonstrated that the prediction accuracies of the metastasis-associated terms, the genes enriched in the metastasis-associated terms, and all the DEGs were 0.875, 0.783 and 0.803, respectively ([Fig. 5](#f5-ijmm-41-03-1233){ref-type="fig"}). Thus, the metastasis-associated terms optimized the number of characteristics without reducing the prediction accuracy. In addition, the KM survival curve demonstrated that the survival times of the samples with significant differences in the metastasis-associated terms were significantly changed (P=0.0279) ([Fig. 6](#f6-ijmm-41-03-1233){ref-type="fig"}). In addition, a regression model was used to predict the samples in GSE81892 and GSE14827. The results demonstrated that the prediction accuracies of the model to OS specimens with obvious resistance and OS specimens with drug sensitivity were 82.4 and 65%, respectively. These indicated that the metastasis-associated terms affected drug sensitivity and had better predictive effects for OS specimens with obvious resistance.

Discussion
==========

In the present study, a total of 840 DEGs (including 420 upregulated and 420 downregulated genes) were identified in the case group compared with the control group. Unsupervised clustering analysis indicated that the classification effect for the samples in the majority of neurons was good. Hierarchical clustering analysis indicated that the significantly enriched terms significantly changed at a functional level during OS metastasis. Regulation of cell migration, nucleotide excision repair, the Wnt signaling pathway, and cell migration were among the top 25 terms exhibiting significant differences. ROC curves indicated that the metastasis-associated terms optimized the number of characteristics without reducing the prediction accuracy. Additionally, the KM survival curve indicated that the survival times of the samples with significantly different metastasis-associated terms also demonstrated significant changes. In addition, the metastasis-associated terms affected drug sensitivity and had better predictive effect for OS specimens with obvious resistance.

The nucleotide excision repair pathway, which repairs bulky lesions and is correlated with platinum-based chemotherapy and tumor progression ([@b30-ijmm-41-03-1233],[@b31-ijmm-41-03-1233]). *ERCC* excision repair 2, *TFIIH* core complex helicase subunit, a member of the nucleotide excision repair pathway, rs1799793 is a marker of OS and is associated with the survival of OS patients following platinum therapy ([@b32-ijmm-41-03-1233]). The Wnt signaling pathway has aberrant activation in OS, which is associated with the development and progression of this type of bone malignancy ([@b33-ijmm-41-03-1233],[@b34-ijmm-41-03-1233]). The genes involved in Wnt and other Wnt signaling pathways have frequent deletions, indicating that the Wnt signaling pathway is genetically inactivated in patients with OS ([@b35-ijmm-41-03-1233]). Therefore, nucleotide excision repair and Wnt signaling pathways may be involved in the pathogenesis of OS.

The present study indicated that *ICAM1*, *PDGFB* and *PDGFRB* were enriched in cell migration and regulation of cell migration. Via promoting the expression of *ICAM1*, chemokine (C-X3-C motif) ligand 1 (termed fractalkine) contributes to migration and metastasis of OS cells, and thus represents a promising therapeutic target for inhibiting OS metastasis ([@b36-ijmm-41-03-1233]). Via the PI3K/Akt signaling pathway, *ICAM1* expression is upregulated by amphiregulin and thus leads to enhanced cell metastasis of OS ([@b37-ijmm-41-03-1233],[@b38-ijmm-41-03-1233]). Kubo *et al* ([@b39-ijmm-41-03-1233]) demonstrate that the expression levels of *PDGF* and *PDGFR* potentially predict the prognosis of OS. Takagi *et al* ([@b40-ijmm-41-03-1233]) observed that platelets promote PDGF function in the proliferation of OS cells via activation of the PDGFR-Akt signaling axis. Thus, *ICAM1*, *PDGFB* and *PDGFRB* may act in OS via cell migration and regulation of cell migration. In the PPI network, there were various interactions (including ICAM1-TGFB1, TGFB1-PDGFB, and PDGFB-PDGFRB). Thus, *ICAM1*, *PDGFB* and *PDGFRB* function in OS via interacting with other genes.

Furthermore, *TGFB1* was enriched in cell migration and regulation of cell migration. The serum level of TGFB in OS patients with metastasis is higher than that in OS patients without metastasis, indicating that *TGFB* may be important in OS ([@b41-ijmm-41-03-1233]). *TGFB2* activity is inhibited by lumican, which subsequently mediates cell adhesion of OS by regulating integrin-β1, phosphorylated SMAD family member 2 (SMAD2) and phosphorylated focal adhesion kinase ([@b42-ijmm-41-03-1233]). Wu *et al* ([@b43-ijmm-41-03-1233]) report that the 29 T\>C single nucleotide polymorphism of the TGFB1 gene is correlated with the incidence and invasion of OS. The TGFB/SMAD3 and p53 signaling pathways are critical for the doxorubicin-induced cytotoxicity in OS cells ([@b44-ijmm-41-03-1233]). Antisense *TGFB1* inhibits matrix metallopeptidase 2 and urokinase expression levels, which suppresses the invasion and metastasis of OS cells ([@b45-ijmm-41-03-1233]). Thus, *TGFB1* contribute to the metastasis of OS via cell migration and regulation of cell migration.

Limited to the number of collected samples, we cannot validate the results of this study in clinical samples. However, we believe that these results based on large data analysis could provide valuable clues for the study of the pathogenesis of metastasis or may aid in the development of novel treatment strategies for OS.

In conclusion, a total of 840 DEGs were identified in the case group. In addition, nucleotide excision repair and the Wnt signaling pathway, as well as cell migration and regulation of cell migration involving *ICAM1*, *PDGFB*, *PDGFRB* and *TGFB1* may represent the metastasis-associated pathways of OS.

![(A) Heat map of hierarchical clustering analysis (horizontal and vertical axes represent similarity distance and OS biopsy specimens before/after metastasis, respectively). (B) Distance map demonstrating the distances between the remaining 36 samples (blue and yellow separately represent close and far distances, respectively). OS, osteosarcoma.](IJMM-41-03-1233-g01){#f1-ijmm-41-03-1233}

![Result of unsupervised clustering analysis based on the self-organization map method. Red and blue represent osteosarcoma biopsy specimens before and after metastasis, respectively.](IJMM-41-03-1233-g02){#f2-ijmm-41-03-1233}

![Protein-protein interaction network constructed for the differentially expressed genes. Red and green represent upregulated and downregulated genes, respectively.](IJMM-41-03-1233-g03){#f3-ijmm-41-03-1233}

![Heat map of hierarchical clustering analysis with functional terms as features. Horizontal and vertical axes represent osteosarcoma biopsy specimens before (yellow)/after (blue) metastasis and the functional terms (red and blue represent upregulation and downregulation, respectively.](IJMM-41-03-1233-g04){#f4-ijmm-41-03-1233}

![Receiver operating characteristic curves. Red curve indicates the prediction accuracies of the recurrent risk-associated terms (pathway); blue curve indicates the prediction accuracies of the genes enriched in the recurrent risk-associated terms (Pathgene); green curve indicates the prediction accuracies of the differentially expressed genes (Siggene). AUC, area under the curve.](IJMM-41-03-1233-g05){#f5-ijmm-41-03-1233}

![Kaplan-Meier survival curves. Red and green represent the predicted high- and low-risk groups, respectively.](IJMM-41-03-1233-g06){#f6-ijmm-41-03-1233}

###### 

The Gene Ontology (GO) terms significantly enriched for the upregulated genes.

  Term                                                            Count   P-value    Gene symbol
  --------------------------------------------------------------- ------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0030334 - regulation of cell migration                       25      2.83E-12   *DLC1*, *PDGFB*, *ENPP2*, *KIT*, *ADA*, *TGFB1*, *ACE*, *S1PR1*, *INS*, *TEK*, *ROBO4*, *TIE1*, *LAMB1*, *ICAM1*, *PTPRM*, *IGF2*, *VASH1*, *THY1*, *KDR*, *LAMA4*, *LAMA3*, *CLIC4*, *PDGFRB*, *ARAP3*, *IGFBP3*, *F2R*
  GO:0001568 - blood vessel development                           27      2.74E-10   *EMCN*, *CAV1*, *ATP5B*, *COL3A1*, *WASF2*, *ELK3*, *CDH5*, *GJC1*, *PTK2*, *ACE*, *S1PR1*, *CD44*, *ROBO4*, *LOX*, *PLXND1*, *EPAS1*, *MYO1E*, *MMP19*, *COL15A1*, *UBP1*, *THY1*, *KDR*, *LAMA4*, *BGN*, *PLXDC1*, *NOTCH4*, *ENG*
  GO:0001944 - vasculature development                            27      4.67E-10   *EMCN*, *CAV1*, *ATP5B*, *COL3A1*, *WASF2*, *ELK3*, *CDH5*, *GJC1*, *PTK2*, *ACE*, *S1PR1*, *CD44*, *ROBO4*, *LOX*, *PLXND1*, *EPAS1*, *MYO1E*, *MMP19*, *COL15A1*, *UBP1*, *THY1*, *KDR*, *LAMA4*, *BGN*, *PLXDC1*, *NOTCH4*, *ENG*
  GO:0048514 - blood vessel morphogenesis                         22      4.70E-08   *CAV1*, *EMCN*, *EPAS1*, *ATP5B*, *MYO1E*, *MMP19*, *WASF2*, *COL15A1*, *ELK3*, *UBP1*, *GJC1*, *THY1*, *KDR*, *PTK2*, *ACE*, *S1PR1*, *BGN*, *PLXDC1*, *NOTCH4*, *ROBO4*, *PLXND1*, *ENG*
  GO:0016477 - cell migration                                     24      2.82E-07   *ICAM1*, *PDGFB*, *ATP5B*, *PODXL*, *WASF2*, *ITGA1*, *KIT*, *TGFB1*, *KDR*, *VCAM1*, *NCK2*, *EDNRB*, *PTK2*, *ITGA6*, *CD44*, *CD34*, *ITGA5*, *FYN*, *PDGFRB*, *MSN*, *LAMC1*, *ENG*, *MYH10*, *THBS4*
  GO:0007167 - enzyme linked receptor protein signaling pathway   24      1.11E-05   *PDGFB*, *EFNA1*, *ADCYAP1R1*, *COL3A1*, *FKBP1A*, *KIT*, *EPHB3*, *EPHB4*, *TGFB1*, *PTK2*, *INS*, *TEK*, *TIE1*, *PTPRE*, *SOCS2*, *MYO1E*, *IGF2*, *KDR*, *LEFTY1*, *NCK2*, *PRLR*, *PDGFRB*, *TGFB1I1*, *ENG*, *GFRA2*
  GO:0009966 - regulation of signal transduction                  42      4.27E-05   *DLC1*, *FGD2*, *CAV1*, *PDGFB*, *TBC1D9*, *EFNA1*, *AGFG2*, *PREX2*, *ASAP2*, *ASAP1*, *ITPKB*, *FKBP1A*, *KIT*, *CD74*, *MCF2L*, *TGFB1*, *ADA*, *S1PR1*, *NOD1*, *INS*, *RAPGEF5*, *RHOC*, *TRAF5*, *RAMP2*, *SOCS2*, *PSD3*, *ITGA1*, *IGF2*, *ARHGEF15*, *CD40*, *THY1*, *NCK2*, *TNFSF10*, *ARRB1*, *RGS5*, *TGFB1I1*, *GRK5*, *IGFBP2*, *ARAP3*, *ENG*, *IGFBP3*, *MAP3K11*, *F2R*
  GO:0009888 - tissue development                                 31      8.58E-04   *DLC1*, *CAV1*, *COL3A1*, *FKBP1A*, *TIMP3*, *TGFB1*, *GJC1*, *EDNRB*, *S1PR1*, *CD44*, *SERPINE1*, *TIE1*, *F11R*, *BMP1*, *HSPG2*, *MECOM*, *SNAI2*, *COL5A2*, *FZD6*, *KDR*, *NOTCH3*, *LAMA3*, *SPRR1B*, *NOTCH4*, *PDGFRB*, *LAMC1*, *TGFB1I1*, *ENG*, *FABP5*, *F2R*, *MYH10*
  GO:0008284 - positive regulation of cell proliferation          22      1.26E-03   *GNAI2*, *PDGFB*, *BTC*, *CDK6*, *IGF2*, *KIT*, *CD40*, *PNP*, *ADA*, *TGFB1*, *KDR*, *VCAM1*, *NCK2*, *S1PR1*, *INS*, *NOTCH4*, *AVPR1A*, *PDGFRB*, *LAMC1*, *LAMB1*, *TRAF5*, *THPO*, *F2R*
  GO:0043067 - regulation of programmed cell death                34      2.71E-03   *DLC1*, *FGD2*, *BID*, *CADM1*, *BTC*, *KIT*, *TIMP3*, *ADA*, *TGFB1*, *MCF2L*, *CD74*, *EDNRB*, *PEA15*, *PCGF2*, *NOD1*, *CASP4*, *CD44*, *INS*, *TRAF5*, *PHLDA1*, *HIP1*, *GIMAP5*, *ACTN4*, *SOCS2*, *ITGA1*, *IGF2*, *NLRP1*, *CASP10*, *TNFSF10*, *PRLR*, *ETS1*, *IGFBP3*, *FAIM2*, *F2R*, *MAP3K11*
  GO:0007166 - cell surface receptor linked signal transduction   64      3.44E-03   *PDGFB*, *EFNA1*, *PREX2*, *WASF2*, *LPAR4*, *ITPKB*, *TGFB1*, *LPHN2*, *EDNRB*, *S1PR1*, *ELTD1*, *TIE1*, *RAMP2*, *GPR176*, *SOCS2*, *CD40*, *OR10J1*, *THY1*, *LEFTY1*, *NCK2*, *CPE*, *CHRM2*, *LPAR6*, *GPR56*, *PDGFRB*, *TGFB1I1*, *GNAI2*, *GNAI1*, *ENPP2*, *ADCYAP1R1*, *COL3A1*, *GNG11*, *FKBP1A*, *GAST*, *KIT*, *EPHB3*, *EPHB4*, *APLNR*, *PTK2*, *DOCK1*, *INS*, *TEK*, *PTPRE*, *MYO1E*, *ITGA1*, *IGF2*, *OR51E2*, *CENPI*, *KDR*, *FZD6*, *NOTCH3*, *SEMA6A*, *LAMA3*, *PRLR*, *ITGA6*, *FYN*, *ITGA5*, *HEYL*, *NOTCH4*, *AVPR1A*, *GRK5*, *ENG*, *GFRA2*, *GPR116*, *F2R*
  GO:0042981 - regulation of apoptosis                            33      4.22E-03   *DLC1*, *FGD2*, *BID*, *CADM1*, *BTC*, *TIMP3*, *ADA*, *TGFB1*, *MCF2L*, *CD74*, *EDNRB*, *PEA15*, *PCGF2*, *NOD1*, *CASP4*, *CD44*, *INS*, *TRAF5*, *PHLDA1*, *HIP1*, *GIMAP5*, *ACTN4*, *SOCS2*, *ITGA1*, *IGF2*, *NLRP1*, *CASP10*, *TNFSF10*, *PRLR*, *ETS1*, *IGFBP3*, *FAIM2*, *F2R*, *MAP3K11*
  hsa04514: Cell adhesion molecules (CAMs)                        22      2.32E-09   *F11R*, *ICAM1*, *PTPRM*, *CADM1*, *ICAM2*, *CLDN5*, *HLA-A*, *HLA-C*, *CD40*, *HLA-B*, *HLA-E*, *HLA-DMA*, *HLA-DQA1*, *HLA-G*, *CDH5*, *VCAM1*, *ITGA6*, *CD34*, *PECAM1*, *HLA-DPA1*, *HLA-DPB1*, *JAM2*, *HLA-DRA*
  hsa04512: ECM-receptor interaction                              17      1.49E-08   *COL4A2*, *COL4A1*, *COL3A1*, *ITGA1*, *HSPG2*, *COL5A2*, *VWF*, *LAMA4*, *LAMA3*, *CD44*, *ITGA6*, *ITGA5*, *COL6A3*, *SV2B*, *LAMC1*, *LAMB1*, *THBS4*
  hsa05200: Pathways in cancer                                    19      3.04E-02   *BID*, *COL4A2*, *COL4A1*, *PDGFB*, *EPAS1*, *CDK6*, *KIT*, *MECOM*, *TGFB1*, *FZD6*, *PTK2*, *LAMA4*, *LAMA3*, *ITGA6*, *ETS1*, *PDGFRB*, *LAMC1*, *LAMB1*, *TRAF5*

###### 

The KEGG pathways significant enriched for the upregulated genes.

  Term                                       Count   P-value    Gene symbol
  ------------------------------------------ ------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa04514: Cell adhesion molecules (CAMs)   22      2.32E-09   *F11R*, *ICAM1*, *PTPRM*, *CADM1*, *ICAM2*, *CLDN5*, *HLA-A*, *HLA-C*, *CD40*, *HLA-B*, *HLA-E*, *HLA-DMA*, *HLA-DQA1*, *HLA-G*, *CDH5*, *VCAM1*, *ITGA6*, *CD34*, *PECAM1*, *HLA-DPA1*, *HLA-DPB1*, *JAM2*, *HLA-DRA*
  hsa04512: ECM-receptor interaction         17      1.49E-08   *COL4A2*, *COL4A1*, *COL3A1*, *ITGA1*, *HSPG2*, *COL5A2*, *VWF*, *LAMA4*, *LAMA3*, *CD44*, *ITGA6*, *ITGA5*, *COL6A3*, *SV2B*, *LAMC1*, *LAMB1*, *THBS4*
  hsa05200: Pathways in cancer               19      3.04E-02   *BID*, *COL4A2*, *COL4A1*, *PDGFB*, *EPAS1*, *CDK6*, *KIT*, *MECOM*, *TGFB1*, *FZD6*, *PTK2*, *LAMA4*, *LAMA3*, *ITGA6*, *ETS1*, *PDGFRB*, *LAMC1*, *LAMB1*, *TRAF5*

###### 

The Gene Ontology (GO) terms significant enriched for the downregulated genes.

  Term                                                                     Count   P-value    Gene symbol
  ------------------------------------------------------------------------ ------- ---------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0016070 - RNA metabolic process                                       49      1.11E-06   *EIF2C2*, *TCOF1*, *SYNCRIP*, *SKIV2L2*, *WTAP*, *SART1*, *SMNDC1*, *INTS8*, *IMP3*, *RRP1B*, *ASH2L*, *TRMT5*, *QKI*, *SUPT5H*, *IMP4*, *NFX1*, *KHDRBS3*, *AR*, *ZCCHC11*, *PRPF39*, *MED13*, *HNRNPU*, *C4ORF23*, *EIF4G1*, *HNRPDL*, *CELF1*, *SNRPF*, *MYNN*, *CPSF3L*, *ELL*, *SR140*, *WBP11*, *HSPA1A*, *POLR2C*, *PPAN*, *RPL7*, *PRKRA*, *C19ORF29*, *GTF3C5*, *TCEA1*, *SNRNP70*, *SNRNP35*, *NFATC3*, *PRPF40A*, *SMG5*, *TAF7*, *PPP1R8*, *POP1*, *DDX54*
  GO:0006396 - RNA processing                                              34      2.11E-06   *CPSF3L*, *EIF2C2*, *SR140*, *SYNCRIP*, *SKIV2L2*, *WBP11*, *WTAP*, *POLR2C*, *SART1*, *SMNDC1*, *INTS8*, *PPAN*, *IMP3*, *RRP1B*, *RPL7*, *TRMT5*, *PRKRA*, *C19ORF29*, *QKI*, *SNRNP70*, *SNRNP35*, *IMP4*, *PRPF40A*, *KHDRBS3*, *ZCCHC11*, *PRPF39*, *HNRNPU*, *C4ORF23*, *HNRPDL*, *PPP1R8*, *POP1*, *CELF1*, *DDX54*, *SNRPF*
  GO:0010468 - regulation of gene expression                               97      5.20E-04   *EIF2C2*, *ARNT2*, *STAT5B*, *MORF4L2*, *NAA15*, *SYNCRIP*, *CNOT1*, *CBX7*, *ZNF304*, *CRY2*, *DIRAS3*, *MED28*, *SUPT5H*, *EIF2B4*, *MYST3*, *GTPBP4*, *MED13*, *HNRNPU*, *BAZ1B*, *ZNF238*, *ZNF239*, *MNX1*, *MGA*, *ZZZ3*, *CELF1*, *PAF1*, *MYNN*, *SIVA1*, *CNBP*, *ELL*, *ADORA2A*, *HOXA11*, *TH1L*, *CYTL1*, *KEAP1*, *NR1H2*, *LYL1*, *EIF3H*, *PRKRA*, *LHX5*, *DNMT3A*, *TAF7*, *ZBTB44*, *UIMC1*, *SAFB2*, *HDAC5*, *NRF1*, *EIF4H*, *ATF7*, *SMARCC2*, *RFX1*, *DDX54*, *SOX21*, *E2F6*, *MITF*, *CTCF*, *PHF20*, *ZKSCAN5*, *CRX*, *AES*, *ASH2L*, *ACTR5*, *CCDC101*, *ZNF146*, *QKI*, *NFX1*, *ZNF281*, *AR*, *KHDRBS3*, *ZCCHC11*, *GMEB1*, *ZNF143*, *HNRPDL*, *EIF4G1*, *MED6*, *BPTF*, *CARM1*, *MTDH*, *ZBTB11*, *SCML1*, *GCN1L1*, *MORC3*, *HMGXB4*, *PPP3CB*, *TCEA1*, *THAP1*, *KDM3B*, *SNRNP70*, *NFATC3*, *TERF2*, *NACC2*, *CEBPE*, *SIRT4*, *ZNF669*, *PKNOX1*, *PPP1R8*, *RBM15*
  GO:0016071 - mRNA metabolic process                                      21      9.32E-04   *EIF2C2*, *KHDRBS3*, *SMG5*, *SYNCRIP*, *PRPF39*, *WBP11*, *SKIV2L2*, *HSPA1A*, *WTAP*, *POLR2C*, *HNRNPU*, *SART1*, *SMNDC1*, *PPP1R8*, *C19ORF29*, *QKI*, *CELF1*, *SNRNP35*, *SNRNP70*, *SNRPF*, *PRPF40A*
  GO:0010605 - negative regulation of macromolecule metabolic process      33      1.34E-03   *HCRT*, *EIF2C2*, *MTDH*, *E2F6*, *TH1L*, *CTCF*, *ANAPC10*, *NR1H2*, *AES*, *PSMB1*, *PRKRA*, *SUPT5H*, *TERF2*, *EIF2B4*, *MYST3*, *NFX1*, *ZNF281*, *DNMT3A*, *ANAPC2*, *GTPBP4*, *NACC2*, *ZCCHC11*, *TAF7*, *SIRT4*, *UIMC1*, *HDAC5*, *ZNF238*, *BPTF*, *PSMA5*, *PSMC3*, *SMARCC2*, *CELF1*, *RBM15*
  GO:0030163 - protein catabolic process                                   29      1.68E-03   *RAD23B*, *KIAA0368*, *ATG12*, *UBE3B*, *UBE2V2*, *ANAPC10*, *UBE2D3*, *LONP1*, *USP27X*, *PSMB1*, *OTUD7B*, *RNF167*, *FBXO42*, *FBXO9*, *TPRKB*, *CUL1*, *NFX1*, *AXIN1*, *ANAPC2*, *SOCS6*, *SOCS5*, *KCMF1*, *CUL4A*, *PSMC3*, *PSMA5*, *UBR5*, *SIAH1*, *PCYOX1*, *FBXO11*
  GO:0043632 - modification-dependent macromolecule catabolic process      27      2.20E-03   *RAD23B*, *ATG12*, *UBE3B*, *KIAA0368*, *UBE2V2*, *ANAPC10*, *LONP1*, *USP27X*, *UBE2D3*, *PSMB1*, *OTUD7B*, *RNF167*, *FBXO42*, *FBXO9*, *CUL1*, *NFX1*, *ANAPC2*, *SOCS6*, *SOCS5*, *KCMF1*, *CUL4A*, *PSMC3*, *PSMA5*, *UBR5*, *SIAH1*, *PCYOX1*, *FBXO11*
  GO:0010629 - negative regulation of gene expression                      24      3.64E-03   *ZNF281*, *DNMT3A*, *EIF2C2*, *NACC2*, *ZCCHC11*, *MTDH*, *E2F6*, *TH1L*, *TAF7*, *SIRT4*, *CTCF*, *UIMC1*, *NR1H2*, *HDAC5*, *AES*, *ZNF238*, *BPTF*, *PRKRA*, *SMARCC2*, *CELF1*, *SUPT5H*, *RBM15*, *MYST3*, *NFX1*
  GO:0019219 - regulation of nucleic acid metabolic process                91      4.03E-03   *EIF2C2*, *SOX21*, *E2F6*, *MORF4L2*, *MITF*, *STAT5B*, *ARNT2*, *NAA15*, *SYNCRIP*, *CNOT1*, *CTCF*, *PHF20*, *CBX7*, *ZKSCAN5*, *CRX*, *ZNF304*, *CRY2*, *AES*, *ASH2L*, *MED28*, *ACTR5*, *CCDC101*, *ZNF146*, *SUPT5H*, *MYST3*, *NFX1*, *ZNF281*, *AR*, *KHDRBS3*, *GTPBP4*, *GMEB1*, *ZNF143*, *MED13*, *HNRNPU*, *MED6*, *HNRPDL*, *ZNF238*, *BPTF*, *BAZ1B*, *ZNF239*, *MNX1*, *MGA*, *ZZZ3*, *PAF1*, *CARM1*, *MYNN*, *SIVA1*, *HCRT*, *CNBP*, *MTDH*, *ADORA2A*, *ELL*, *ZBTB11*, *HOXA11*, *SCML1*, *PTH1R*, *TH1L*, *CYTL1*, *UBE2V2*, *KEAP1*, *NR1H2*, *LYL1*, *HMGXB4*, *LHX5*, *THAP1*, *TCEA1*, *KDM3B*, *SNRNP70*, *NFATC3*, *TERF2*, *GUCA1B*, *DNMT3A*, *GUCA1A*, *NACC2*, *CEBPE*, *TAF7*, *SIRT4*, *ZNF669*, *ZBTB44*, *UIMC1*, *SAFB2*, *HDAC5*, *NRF1*, *P2RY11*, *PKNOX1*, *PPP1R8*, *ATF7*, *SMARCC2*, *RFX1*, *DDX54*, *RBM15*
  GO:0044257 - cellular protein catabolic process                          27      4.27E-03   *RAD23B*, *ATG12*, *UBE3B*, *KIAA0368*, *UBE2V2*, *ANAPC10*, *LONP1*, *USP27X*, *UBE2D3*, *PSMB1*, *OTUD7B*, *RNF167*, *FBXO42*, *FBXO9*, *CUL1*, *NFX1*, *ANAPC2*, *SOCS6*, *SOCS5*, *KCMF1*, *CUL4A*, *PSMC3*, *PSMA5*, *UBR5*, *SIAH1*, *PCYOX1*, *FBXO11*
  GO:0010558 - negative regulation of macromolecule biosynthetic process   25      4.95E-03   *HCRT*, *EIF2C2*, *MTDH*, *E2F6*, *TH1L*, *CTCF*, *NR1H2*, *AES*, *SUPT5H*, *EIF2B4*, *TERF2*, *NFX1*, *MYST3*, *ZNF281*, *DNMT3A*, *GTPBP4*, *NACC2*, *TAF7*, *SIRT4*, *UIMC1*, *HDAC5*, *ZNF238*, *BPTF*, *SMARCC2*, *RBM15*
  GO:0031325 - positive regulation of cellular metabolic process           35      6.60E-03   *CNBP*, *ADORA2A*, *MORF4L2*, *ARNT2*, *MITF*, *STAT5B*, *NAA15*, *CYTL1*, *CTCF*, *ANAPC10*, *CRX*, *NR1H2*, *PSMB1*, *TCEA1*, *CD24*, *SUPT5H*, *NFATC3*, *TERF2*, *CUL1*, *MYST3*, *AXIN1*, *ANAPC2*, *AR*, *TAF7*, *MED13*, *UIMC1*, *MED6*, *HDAC5*, *PKNOX1*, *BPTF*, *PSMA5*, *PSMC3*, *SMARCC2*, *TNK2*, *RBM15*
  GO:0031327 - negative regulation of cellular biosynthetic process        25      6.64E-03   *HCRT*, *EIF2C2*, *MTDH*, *E2F6*, *TH1L*, *CTCF*, *NR1H2*, *AES*, *SUPT5H*, *EIF2B4*, *TERF2*, *NFX1*, *MYST3*, *ZNF281*, *DNMT3A*, *GTPBP4*, *NACC2*, *TAF7*, *SIRT4*, *UIMC1*, *HDAC5*, *ZNF238*, *BPTF*, *SMARCC2*, *RBM15*
  GO:0031324 - negative regulation of cellular metabolic process           30      6.85E-03   *HCRT*, *EIF2C2*, *MTDH*, *E2F6*, *TH1L*, *CTCF*, *ANAPC10*, NR1H2, *AES*, *PSMB1*, *SUPT5H*, *EIF2B4*, *TERF2*, *MYST3*, *NFX1*, *ZNF281*, *DNMT3A*, *ANAPC2*, *GTPBP4*, *NACC2*, *TAF7*, *SIRT4*, *UIMC1*, *HDAC5*, *ZNF238*, *BPTF*, *PSMC3*, *PSMA5*, *SMARCC2*, *RBM15*
  GO:0044267 - cellular protein metabolic process                          77      7.19E-03   *EIF2C2*, *KIAA0368*, *NAA15*, *ART3*, *USP27X*, *LONP1*, *CRY2*, *FAU*, *SIK2*, *EIF2B4*, *CUL1*, *MYST3*, *NFX1*, *ANAPC2*, *SGK2*, *ROCK2*, *SECISBP2*, *SOCS6*, *SOCS5*, *DAPK3*, *ST13*, *EIF4G1*, *BAZ1B*, *PSMA5*, *UBR5*, *SIAH1*, *PAF1*, *PCYOX1*, *CARM1*, *TM4SF4*, *FBXO11*, *RAD23B*, *UBE3B*, *ATG12*, *STK11*, *BLK*, *CAMK2G*, *MAPKAPK5*, *ANAPC10*, *UBE2V2*, *AKAP9*, *MTMR3*, *UBE2D3*, *EIF3G*, *RPL7*, *PSMB1*, *MORC3*, *EIF3H*, *SH3GLB1*, *PRKRA*, *OTUD7B*, *PPP3CB*, *RNF167*, *FBXO42*, *RSL24D1*, *EIF3J*, *FBXO9*, *OBSCN*, *P4HB*, *ALPK3*, *RYK*, *EEF1A2*, *SIRT4*, *OXSR1*, *LOC653566*, *UIMC1*, *HDAC5*, *NMT1*, *CUL4A*, *KCMF1*, *RPL13A*, *PSMC3*, *PPID*, *EIF4H*, *CCT8*, *LGTN*, *TNK2*
  GO:0031326 - regulation of cellular biosynthetic process                 93      7.26E-03   *EIF2C2*, *SOX21*, *E2F6*, *MORF4L2*, *STAT5B*, *ARNT2*, *MITF*, *NAA15*, *CNOT1*, *CTCF*, *PHF20*, *CBX7*, *ZKSCAN5*, *CRX*, *ZNF304*, *CRY2*, *AES*, *ASH2L*, *MED28*, *ACTR5*, *CCDC101*, *ZNF146*, *QKI*, *SUPT5H*, *EIF2B4*, *MYST3*, *NFX1*, *ZNF281*, *AR*, *KHDRBS3*, *GTPBP4*, *GMEB1*, *ZNF143*, *MED13*, *MED6*, *HNRPDL*, *EIF4G1*, *ZNF238*, *BPTF*, *BAZ1B*, *ZNF239*, *MNX1*, *MGA*, *ZZZ3*, *PAF1*, *CARM1*, *MYNN*, *SIVA1*, *HCRT*, *CNBP*, *MTDH*, *ADORA2A*, *ELL*, *ZBTB11*, *HOXA11*, *SCML1*, *PTH1R*, *TH1L*, *CYTL1*, *KEAP1*, *GCN1L1*, *NR1H2*, *EIF3H*, *LYL1*, *HMGXB4*, *LHX5*, *THAP1*, *TCEA1*, *KDM3B*, *NFATC3*, *TERF2*, *GUCA1B*, *DNMT3A*, *GUCA1A*, *NACC2*, *CEBPE*, *TAF7*, *SIRT4*, *ZNF669*, *ZBTB44*, *UIMC1*, *SAFB2*, *HDAC5*, *NRF1*, *P2RY11*, *PKNOX1*, *PPP1R8*, *EIF4H*, *ATF7*, *SMARCC2*, *RFX1*, *DDX54*, *RBM15*
  GO:0010604 - positive regulation of macromolecule metabolic process      34      7.79E-03   *CNBP*, *MORF4L2*, *ARNT2*, *MITF*, *STAT5B*, *NAA15*, *CYTL1*, *CTCF*, *ANAPC10*, *CRX*, *NR1H2*, *PSMB1*, *TCEA1*, *CD24*, *SUPT5H*, *NFATC3*, *TERF2*, *CUL1*, *MYST3*, *AXIN1*, *ANAPC2*, *AR*, *TAF7*, *MED13*, *UIMC1*, *MED6*, *HDAC5*, *PKNOX1*, *BPTF*, *PSMA5*, *PSMC3*, *SMARCC2*, *TNK2*, *RBM15*
  GO:0045893 - positive regulation of transcription, DNA-dependent         22      7.98E-03   *AR*, *CNBP*, *MORF4L2*, *ARNT2*, *STAT5B*, *MITF*, *TAF7*, *CYTL1*, *NAA15*, *CTCF*, *MED13*, *CRX*, *NR1H2*, *MED6*, *HDAC5*, *PKNOX1*, *BPTF*, *SMARCC2*, *TCEA1*, *SUPT5H*, *NFATC3*, *RBM15*
  GO:0009890 - negative regulation of biosynthetic process                 25      8.53E-03   *HCRT*, *EIF2C2*, *MTDH*, *E2F6*, *TH1L*, *CTCF*, *NR1H2*, *AES*, *SUPT5H*, *EIF2B4*, *TERF2*, *NFX1*, *MYST3*, *ZNF281*, *DNMT3A*, *GTPBP4*, *NACC2*, *TAF7*, *SIRT4*, *UIMC1*, *HDAC5*, *ZNF238*, *BPTF*, *SMARCC2*, *RBM15*
  GO:0051254 - positive regulation of RNA metabolic process                22      8.70E-03   *AR*, *CNBP*, *MORF4L2*, *ARNT2*, *STAT5B*, *MITF*, *TAF7*, *CYTL1*, *NAA15*, *CTCF*, *MED13*, *CRX*, *NR1H2*, *MED6*, *HDAC5*, *PKNOX1*, *BPTF*, *SMARCC2*, *TCEA1*, *SUPT5H*, *NFATC3*, *RBM15*
  GO:0045934 - negative regulation of nucleic acid metabolic process       23      8.74E-03   *ZNF281*, *DNMT3A*, *HCRT*, *GTPBP4*, *NACC2*, *MTDH*, *E2F6*, *TH1L*, *TAF7*, *SIRT4*, *CTCF*, *UIMC1*, *NR1H2*, *HDAC5*, *AES*, *ZNF238*, *BPTF*, *SMARCC2*, *SUPT5H*, *RBM15*, *TERF2*, *MYST3*, *NFX1*
  GO:0010556 - regulation of macromolecule biosynthetic process            89      9.86E-03   *EIF2C2*, *SOX21*, *E2F6*, *MORF4L2*, *STAT5B*, *ARNT2*, *MITF*, *NAA15*, *CNOT1*, *CTCF*, *PHF20*, *CBX7*, *ZKSCAN5*, *CRX*, *ZNF304*, *CRY2*, *AES*, *ASH2L*, *MED28*, *ACTR5*, *CCDC101*, *ZNF146*, *QKI*, *SUPT5H*, *EIF2B4*, *MYST3*, *NFX1*, *ZNF281*, *AR*, *KHDRBS3*, *GTPBP4*, *GMEB1*, *ZNF143*, *MED13*, *MED6*, *HNRPDL*, *EIF4G1*, *ZNF238*, *BPTF*, *BAZ1B*, *ZNF239*, *MNX1*, *MGA*, *ZZZ3*, *PAF1*, *CARM1*, *MYNN*, *SIVA1*, *HCRT*, *CNBP*, *MTDH*, *ADORA2A*, *ELL*, *ZBTB11*, *HOXA11*, *SCML1*, *TH1L*, *CYTL1*, *KEAP1*, *GCN1L1*, *NR1H2*, *EIF3H*, *LYL1*, *HMGXB4*, *LHX5*, *THAP1*, *TCEA1*, *KDM3B*, *NFATC3*, *TERF2*, *DNMT3A*, *NACC2*, *CEBPE*, *TAF7*, *SIRT4*, *ZNF669*, *ZBTB44*, *UIMC1*, *SAFB2*, *HDAC5*, *NRF1*, *PKNOX1*, *PPP1R8*, *EIF4H*, *ATF7*, *SMARCC2*, *RFX1*, *DDX54*, *RBM15*

###### 

The KEGG pathways significant enriched for the downregulated genes.

  Term                          Count   P-value    Gene symbol
  ----------------------------- ------- ---------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa05416: Viral myocarditis   15      7.85E-08   *BID, ICAM1, CAV1, HLA-A, HLA-C, CD40, HLA-B, HLA-E, HLA-DMA*, *HLA-DQA1, HLA-G, FYN, HLA-DPA1, HLA-DPB1, MYH10, HLA-DRA*
  hsa04510: Focal adhesion      22      3.70E-06   *CAV1, COL4A2, COL4A1, ACTN4, PDGFB, COL3A1, ITGA1, COL5A2*, *KDR, VWF, PTK2, LAMA4, LAMA3, DOCK1, ITGA6, ITGA5, FYN*, *COL6A3, PDGFRB, LAMC1, LAMB1, THBS4*
  hsa04144: Endocytosis         16      1.44E-03   *PSD3, ASAP2, HLA-A, ASAP1, HLA-C, KIT, HLA-B, HLA-E, HLA-G*, *KDR, ARRB1, GRK5, ARAP3, EHD2, EHD3, F2R, EHD4*

###### 

The top 25 terms with significant difference in the osteosarcoma biopsy specimens before/after metastasis.

  Term                                                     P-value
  -------------------------------------------------------- ----------
  Blood vessel development                                 3.01E-05
  Vasculature development                                  8.11E-06
  RNA processing                                           3.97E-05
  Positive regulation of macromolecule metabolic process   1.87E-07
  Negative regulation of gene expression                   6.75E-05
  Regulation of cell migration                             2.15E-05
  Blood vessel morphogenesis                               1.77E-05
  DNA replication                                          3.78E-05
  Nucleotide excision repair                               1.31E-05
  ECM-receptor interaction                                 5.27E-05
  Viral myocarditis                                        3.09E-04
  Protein catabolic process                                7.33E-04
  Oocyte meiosis                                           9.26E-04
  Negative regulation of metabolic process                 1.85E-03
  Mismatch repair                                          2.12E-03
  Negative regulation of cellular biosynthetic process     2.32E-03
  Wnt signaling pathway                                    2.32E-03
  mRNA metabolic process                                   3.70E-03
  Tissue development                                       5.16E-03
  Cell migration                                           5.56E-03
  RNA metabolic process                                    7.41E-03
  Enzyme linked receptor protein signaling pathway         8.33E-03
  Focal adhesion                                           8.77E-03
  Pathways in cancer                                       9.26E-03
  Regulation of apoptosis                                  9.52E-03
